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Chronic heart failure (HF) is characterized by sympathetic overactivity and enhanced circulating catecholamines (CAs), which
significantly increase HF morbidity and mortality. We recently
reported that adrenal G protein-coupled receptor kinase 2 (GRK2)
is up-regulated in chronic HF, leading to enhanced CA release via
desensitization/down-regulation of the chromaffin cell ␣2-adrenergic receptors that normally inhibit CA secretion. We also
showed that adrenal GRK2 inhibition decreases circulating CAs
and improves cardiac inotropic reserve and function. Herein,
we hypothesized that adrenal-targeted GRK2 gene deletion before
the onset of HF might be beneficial by reducing sympathetic activation. To specifically delete GRK2 in the chromaffin cells of the
adrenal gland, we crossed PNMTCre mice, expressing Cre recombinase under the chromaffin cell-specific phenylethanolamine
N-methyltransferase (PNMT) gene promoter, with floxedGRK2
mice. After confirming a significant (⬃50%) reduction of adrenal
GRK2 mRNA and protein levels, the PNMT-driven GRK2 knockout (KO) offspring underwent myocardial infarction (MI) to
induce HF. At 4 weeks post-MI, plasma levels of both norepinephrine and epinephrine were reduced in PNMT-driven GRK2 KO,
compared with control mice, suggesting markedly reduced
post-MI sympathetic activation. This translated in PNMT-driven
GRK2 KO mice into improved cardiac function and dimensions
as well as amelioration of abnormal cardiac ␤-adrenergic receptor
signaling at 4 weeks post-MI. Thus, adrenal-targeted GRK2 gene
KO decreases circulating CAs, leading to improved cardiac function and ␤-adrenergic reserve in post-MI HF. GRK2 inhibition in
the adrenal gland might represent a novel sympatholytic strategy
that can aid in blocking HF progression.
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Despite recent advances in prevention and management of
heart disease, death due to chronic heart failure (HF)3 continues to rise and new and innovative treatments are needed (1, 2).
A salient feature of HF is elevated sympathetic nervous system
(SNS) activity and outflow, reflected by increased circulating
catecholamines (CAs). Initially an adaptive process to compensate for decreased function following cardiac injury through
stimulation of ␤-adrenergic receptors (␤ARs), SNS activation
becomes maladaptive, contributing significantly to disease
morbidity and mortality (3–5). Levels of norepinephrine (NE)
are associated with worsened prognosis in HF (6). Epinephrine
(Epi) and, to a lesser extent, NE secretion from the adrenal
medulla provides essentially all circulating CAs and is a fundamental component of SNS outflow (7, 8). Chronic CA elevation
in the heart causes significant dysregulation of ␤ARs that
include a myriad of molecular abnormalities (9). Included is the
up-regulation of G protein-coupled receptor kinase 2 (GRK2 or
␤ARK1), which contributes significantly to ␤AR and ventricular dysfunction (4, 5).
␣2ARs play a crucial role in autocrine feedback inhibition of
CA release from cardiac sympathetic nerve terminals and from
the adrenal medulla. In the latter tissue, they reside in membranes of chromaffin cells, which are responsible for adrenal
CA production (10, 11). The importance of ␣2AR-mediated
SNS activity regulation in cardiac disease has been well documented in a variety of knock-out (KO) mouse models (12–14),
and in HF patients (15, 16). We recently reported that, in addition to myocardium, GRK2 is up-regulated in the adrenal gland
in animal models of HF, leading to enhanced CA release via
desensitization/down-regulation of the chromaffin cell ␣2ARs
(17). We also showed that adrenal GRK2 inhibition via adenoviral-mediated in vivo gene therapy using the ␤ARKct (a GRK2
inhibitory peptide) (18) acutely decreases circulating CAs and
improves cardiac inotropic reserve and function (17).
In the present study, we posited that adrenal-targeted
GRK2 gene deletion, before the onset of HF, might be bene3

The abbreviations used are: HF, heart failure; SNS, sympathetic nervous system; CA, catecholamine; ␤AR, ␤-adrenergic receptor; ␣2AR, ␣2-adrenergic
receptor; NE, norepinephrine; Epi, epinephrine; GRK2, G protein-coupled
receptor kinase 2; KO, knock-out; PNMT, phenylethanolamine N-methyltransferase; MI, myocardial infarction; WT, wild type; TH, tyrosine hydroxylase; BNP, brain natriuretic peptide; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase.
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Plasma and in Vitro CA Measurements—Plasma NE and epinephrine were determined with the
BI-CAT EIA kit from ALPCO
Diagnostics (Windham, NH), as
described before (17).
Echocardiographic and Hemodynamic Measurements—Two-dimensional guided M-mode and Doppler
echocardiography and closed chest
cardiac catheterization were performed in mice as described (17, 22).
Chromaffin Cell Culture and in
Vitro CA Secretion Assays—Chromaffin cells were isolated from
adrenal glands excised from the
mice and cultured as described previously (17). The purity of cultured
chromaffin cells was assessed morphologically and by immunofluorescence and/or immunoblotting
for endogenous expression of tyrosine hydroxylase; purity was over
FIGURE 1. A, PCR screening in tail genomic DNA from PNMTCre/FloxedGRK2 (PNMTCre/Flox) or control
FloxedGRK2 (Flox) mice for confirmation of PNMT locus insertion of the Cre transgene. An additional lane run 90% in all experiments.
without DNA (H2O), thus serving as negative control for the assay is also shown. B, real-time PCR in total adrenal
␣2AR Density Measurements—
mRNA isolated from 2-month-old PNMT-driven GRK2 KO or control FloxedGRK2 (WT) mice for determination of
Plasma
membranes from excised
total adrenal GRK2 mRNA levels (*, p ⬍ 0.05, n ⫽ 6 mice/litter).
adrenal glands were prepared as
described (17), and saturation bindficial by reducing sympathetic activation. To specifically ing was performed using the ␣2AR-specific antagonist [3H]raudelete GRK2 in the chromaffin cells of the adrenal gland, we wolscine. Data were analyzed by nonlinear regression analysis
took advantage of the Cre/loxP technology (19) and crossed using Prism (GraphPad).
Cardiac ␤AR Density and cAMP Measurements—␤AR denPNMTCre mice, expressing Cre recombinase under the
gene promoter of the chromaffin cell-specific enzyme phe- sity was measured in isolated cardiac plasma membranes using
nylethanolamine N-methyl transferase (PNMT) (20), with 125I-CYP (iodocyanopindolol), as described before (23). CarfloxedGRK2⫹/⫹ mice (21). To induce HF, resultant mice diac cAMP levels were measured with the BIOMOL Cyclic
homozygous for the floxed allele (i.e. PNMTCre⫹/⫺/ AMP PLUS EIA kit (Biomol, Plymouth Meeting, PA), as
floxedGRK2⫹/⫹) and control mice with endogenous GRK2 described (23).
Statistical Analysis—Data are summarized as mean ⫾ S.E.
expression underwent myocardial infarction (MI) and were
studied at 4 weeks post-MI. Our data demonstrate that Comparisons were made using t tests or analysis of variance as
reduction of circulating CAs via adrenal-targeted GRK2 appropriate. A Bonferroni correction was applied to the probgene deletion can improve cardiac function and ␤AR signal- ability values whenever multiple comparisons arose. Values of
p ⬍ 0.05 were considered significant.
ing post-MI, and this sympatholysis is beneficial in HF.

EXPERIMENTAL PROCEDURES
Mouse Generation, PCR Screening, and Real-time PCR—
Screening for the presence of the PNMT-Cre transgene was
done in genomic tail DNA from transgenic mice by PCR using a
specific primer mix, as described before (20). Real-time reverse
transcription-PCR was carried out as described (17).
Western Blotting—Western blotting was performed in protein extracts of whole adrenal glands and hearts using appropriate specific antibodies, as described previously (17).
Surgical MI—All animal procedures and experiments were
performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of Thomas Jefferson
University. MI was induced by high ligation of the left anterior
descending coronary artery, as described previously (22).
MAY 21, 2010 • VOLUME 285 • NUMBER 21

RESULTS
Generation of PNMT-driven GRK2 KO Mice—PNMT-driven
GRK2 KO mice were generated by crossing the PNMT-Cre and
the floxedGRK2⫹/⫹ mouse lines and breeding the offspring to
floxed allele homozygosity. All the mice used in the present
study were heterozygous for the PNMT-Cre allele and homozygous for the floxedGRK2 allele (PNMTCre⫹/⫺/floxGRK2⫹/⫹).
PCR screening in tail genomic DNA confirmed the presence of
the PNMT-Cre allele in the offspring (Fig. 1A). GRK2 gene
deletion induced by adrenal chromaffin cell expression of Cre
recombinase led to a significant (53.1 ⫾ 0.5%) reduction of total
adrenal GRK2 mRNA levels in the PNMT-driven GRK2 KO
mice compared with control wild-type (WT) floxedGRK2⫹/⫹
mice (Fig. 1B). Of note, total adrenal mRNA levels of GRK3 and
GRK5, the two most important of the other ubiquitously
JOURNAL OF BIOLOGICAL CHEMISTRY
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phenotype of PNMT-driven GRK2
KO mice. First, PNMT-driven GRK2
KO mice are viable, reproduce normally, and present without any significant abnormalities. Previously,
we have found that, in HF, adrenal
GRK2 up-regulation is accompanied by significant adrenal hypertrophy and elevated CA biosynthetic activity, as reflected by
tyrosine hydroxylase (TH) up-regulation, the enzyme that catalyzes the
rate-limiting step in CA biosynthesis (7, 8). Therefore, we measured
adrenal size and TH expression in
adult (2-month-old) PNMT-driven
GRK2 KO and WT mice. We found
that chromaffin cell GRK2 deletion
leads to a significant decrease of
adrenal size (Fig. 2C and Table 1). In
addition, adrenal TH is down-regulated to a similar extent (⬃50% at
the protein level) in 2-month-old
PNMT-driven GRK2 KO mice
compared with age-matched control WT mice (Fig. 2, A and B). A full
outline of the overt phenotypic
features of these mice can be found
in Table 1. Taken together, these
results suggest that chromaffin cell
FIGURE 2. A, representative Western blots in total adrenal protein extracts from 2-month-old PNMT-driven GRK2 deletion leads to attenuation
GRK2 KO or control FloxedGRK2 (WT) mice for total adrenal GRK2 or tyrosine hydroxylase (TH) protein levels. of adrenal growth and CA biosynBlots for the housekeeping protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH), as loading control,
are also shown. B, densitometric quantitation of the four independent experiments done in A using GAPDH thetic activity during development.
Adrenal ␣2AR Signaling Status in
levels as normalization control (*, p ⬍ 0.05, versus WT, n ⫽ 4 independent experiments performed in extracts
from 6 adrenals pooled from 3 mice/litter each). C, adrenal weight-to-body weight ratios of these mice (see also PNMT-driven GRK2 KO Mice—We
Table 2) (*, p ⫽ 0.023, n ⫽ 10 mice/litter).
also investigated the impact of chromaffin cell-targeted GRK2 deletion
TABLE 1
on the signaling status of the sympatho-inhibitory ␣2ARs,
Basic phenotypic characteristics of 2-month-old male WT and PNMTwhich regulate CA secretion from these cells (8, 10). Saturadriven GRK2 KO mice
tion ligand binding in plasma membranes from the adrenal
WT
PNMT-driven GRK2 KO
glands of PNMT-driven GRK2 KO mice revealed a signifiHeart weight
140 ⫾ 5.0 mg
136 ⫾ 4.0 mg
cant up-regulation of ␣2ARs compared with age-matched
a
Adrenal weight
2.5 ⫾ 0.2 mg
1.6 ⫾ 0.3 mg
Body weight
27.8 ⫾ 0.9 g
26.9 ⫾ 1.0 g
control WT mice (Fig. 3A). Consistent with this, in vitro CA
Liver weight
2.1 ⫾ 0.2 g
2.2 ⫾ 0.2 g
secretion assays in chromaffin cells isolated and cultured
Lung weight
175 ⫾ 13 mg
181 ⫾ 11 mg
from the adrenals of these mice showed that, in cells derived
Kidney weight
630 ⫾ 71 mg
645 ⫾ 75 mg
a
p ⬍ 0.05 versus WT, n ⫽ 10. Note: The basic cardiac functional parameters of these
from PNMT-driven GRK2 KOs, the ␣2AR agonist UK14304
mice are presented in Table 2 (see columns for Sham/WT and Sham/KO of Table 2).
is capable of producing a larger (maximal) inhibition of
expressed GRKs (4), were unchanged (data not shown), con- nicotine-induced CA secretion compared with WT mousefirming the specificity of this genetic deletion approach as well derived chromaffin cells (Fig. 3B). Taken together, these
as the fact that it did not cause any compensatory changes in the experiments confirm that the absence of GRK2 from the
levels of other adrenal GRKs when GRK2 was lost. Importantly, chromaffin cells of PNMT-driven GRK2 KO mice leads to
Western blotting of total adrenal protein extracts from PNMT- increases in both functional ␣2AR number and ␣2AR signaldriven GRK2 KO and WT mice confirmed a significant loss ing/function in these cells, thus providing proof of concept
(⬃50%) of GRK2 protein consistent with the loss of GRK2 gene for the generation of these mice.
Levels of Post-MI HF Sympathetic Activation in PNMTexpression in only the chromaffin cells (Fig. 2, A and B).
Adrenal Phenotypic Characterization of PNMT-driven GRK2 driven GRK2 KO Mice—We have previously reported that
KO Mice—After confirming the success of GRK2 gene deletion adrenal GRK2 is an important regulator of adrenal CA secrein CA-producing chromaffin cells, we investigated the adrenal tion and hence of circulating CA levels, both in normal animals

16380 JOURNAL OF BIOLOGICAL CHEMISTRY

VOLUME 285 • NUMBER 21 • MAY 21, 2010

Adrenal GRK2 Gene Deletion and Heart Failure
In Vivo Cardiac Function 4 Weeks
after MI—We next investigated the
impact of reduced post-MI circulating CA levels in PNMT-driven
GRK2 KO mice on the development
of cardiac dysfunction. As shown in
Fig. 5A, cardiac ejection fraction is
significantly increased in KO mice
compared with WT mice (⬎10%
improvement) at 4 weeks post-MI,
whereas both groups of shamoperated animals exhibited similar
ejection fraction values. Further,
post-MI left ventricular (LV) remodeling was slightly but significantly attenuated in KO mice compared with WT mice as indicated by
FIGURE 3. A, plasma membrane ␣2AR density in the adrenal glands of 2-month-old PNMT-driven GRK2 KO or the reduction of LV end-diastolic
control FloxedGRK2 (WT) mice. Nonspecific binding was determined in the presence of 0.4 mM phentolamine (*, diameter (Fig. 5B). Additionally, in
p ⬍ 0.05, versus WT, n ⫽ 3 independent experiments, performed with 8 adrenals pooled from 4 mice/litter
each). Data are expressed as mean ⫾ S.E. B, in vitro catecholamine secretion from chromaffin cells isolated from vivo cardiac catheterization of these
these mice after nicotine treatment, following pretreatment with vehicle (Nicotine) or with 10 M UK14304 mice at 4 weeks post-MI revealed
(UK14304 ⫹ Nicotine). UK14304 pretreatment alone had no effect (data not shown) (*, p ⬍ 0.05, versus WT/nic- markedly decreased basal and isootine, **, p ⬍ 0.05, versus WT/UK14304 ⫹ nicotine, n ⫽ 3 independent experiments, performed with cells
proterenol-induced cardiac conisolated from 10 adrenals pooled from 5 mice/litter each).
tractility in both groups compared
with sham animals (Fig. 5C). Importantly, although basal ⫹dP/dtmax
responses were similar between
PNMT-driven GRK2 KO and WT
mice post-MI, PNMT-driven GRK2
KO mice had significantly improved
responsiveness to isoproterenol
compared with post-MI WT mice
(Fig. 5C).
Of note, LV infarct size was simiFIGURE 4. Plasma circulating norepinephrine and epinephrine levels in normal, sham-operated (Sham) lar between the two groups at 24 h
or in 4-week post-MI HF (MI) PNMT-driven GRK2 KO (PNMT GRK2 KO) and control FloxedGRK2 (WT) mice. post-MI (Fig. 6), and at 4 weeks
*, p ⬍ 0.05, versus Sham-either genotype; **, p ⬍ 0.05, versus WT MI, n ⫽ 6 mice/group.
post-MI (data not shown), indicating that this improvement in carand in HF (17, 24). Thus, we investigated the impact of GRK2 diac function observed in PNMT-driven GRK2 KOs at 4 weeks
loss in chromaffin cells on circulating plasma CA levels. We post-MI was not due to differences in initial myocardial damage
measured CA levels in PNMT-driven GRK2 KO and WT mice caused by the coronary artery ligation or in viable/functional
under basal conditions (using Sham-operated mice) and also 4 myocardial mass between the two groups. Table 2 provides a
weeks after surgically induced MI. Interestingly, plasma levels complete outline of the in vivo echocardiographic and hemoof both NE and Epi were similar between Sham WT and dynamic parameters of the sham and 4-week post-MI HF mice
PNMT-driven GRK2 KO mice (Fig. 4). This is consistent with within both groups. Taken together, the above physiological
the reported finding that mono-allelic Cre insertion into the data suggest that cardiac function and ␤-adrenergic-stimulated
PNMT locus does not result in changes of the levels of either inotropic reserve at 4 weeks post-MI are significantly improved
catecholamine (20). Indeed, plasma levels of both NE and Epi by the reduction in circulating CA levels due to the chromaffin
were similar between the control WT floxedGRK2⫹/⫹ used in cell-targeted GRK2 deletion. In other words, there is less carthis study and PNMT-Cre⫹/⫺ mice (data not shown). Follow- diac dysfunction 4 weeks post-MI when CA levels are decreased
ing MI (4 weeks), we found that overall survival post-MI was due to a loss of adrenal GRK2 expression.
similar in both groups of mice (data not shown), however, we
Myocardial ␤-Adrenergic Signaling Status at 4 Weeks
found a significant difference in plasma CAs 4 weeks post-MI as Post-MI—We also examined whether the observed improveboth NE and Epi levels were significantly lower in PNMT- ment in cardiac function of post-MI PNMT-driven GRK2 KO
driven GRK2 KO mice compared with WT mice (Fig. 4). This mice translated into positive alteration of cardiac ␤AR signaling
result strongly suggests that PNMT-driven GRK2 deletion at the molecular level, because lower sympathetic overdrive
results in significant attenuation of post-MI sympathetic acti- during HF progression could mean less ␤AR desensitization
vation/increased outflow.
and down-regulation. Accordingly, hearts from both sham-opMAY 21, 2010 • VOLUME 285 • NUMBER 21
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FIGURE 5. A, ejection fraction (EF %) of sham-operated (sham) or of 4-week post-MI HF (MI) PNMT-driven GRK2 KO (PNMT GRK2 KO) and control FloxedGRK2 (WT)
mice (*, p ⫽ 0.005, versus WT MI, n ⫽ 10 mice/group). B, LV end diastolic diameter (LVEDD) of these mice (*, p ⬍ 0.05, versus sham; **, p ⬍ 0.05, versus WT MI, n ⫽
10 mice/group). C, basal and maximal dose of isoproterenol (Max. Iso)-stimulated ⫹ dP/dtmax responses of these mice (*, p ⬍ 0.05, versus sham; **, p ⬍ 0.05,
versus Max. Iso/MI WT, n ⫽ 7 mice/group).

erated and HF mouse lines were excised at 4 weeks post-MI,
and total ␤AR density in plasma membranes isolated from
these hearts was measured. As expected, HF caused a marked
cardiac ␤AR down-regulation in both mouse lines at 4 weeks
post-MI, compared with healthy sham animals (Fig. 7A). However, in post-MI failing KO hearts this ␤AR down-regulation
was significantly attenuated compared with control WT hearts
(Fig. 7A). In addition, we also measured total steady-state
cAMP levels in these hearts. cAMP is a second messenger activated by myocardial ␤ARs crucial for their pro-contractile signaling (3, 4). As shown in Fig. 7B, myocardial cAMP levels in HF
control WT hearts were significantly reduced compared with
sham hearts, consistent with impaired ␤AR signaling in HF.
Cardiac cAMP levels of HF PNMT-driven GRK2 KO mice however were essentially restored to the levels of sham hearts (Fig.
7B), indicating a marked amelioration of cardiac ␤AR signaling
in adrenal-targeted GRK2-depleted mice at 4 weeks post-MI. It
is important to note that the levels of cAMP in PNMT-driven
GRK2 KO hearts were not elevated above sham (non-failing)
heart levels and that levels appear to be normalized (Fig. 7B).
Finally, we measured myocardial GRK2 levels and found that
GRK2 was significantly increased in HF control WT hearts,
again as expected (Fig. 7, C and D). Interestingly, GRK2 levels in

16382 JOURNAL OF BIOLOGICAL CHEMISTRY

PNMT-driven GRK2 KO hearts, albeit no different from WT
hearts in sham healthy animals, were markedly reduced at 4
weeks post-MI compared with WT hearts at the same time
point, to even below the levels of sham hearts (Fig. 7, C and D),
suggesting a complete prevention and/or reversal of the contractility-suppressive cardiac GRK2 up-regulation in failing
PNMT-driven GRK2 KO hearts. Taken together, these results
indicate that the reduction of catecholaminergic stimulation of
the failing heart by the adrenal-specific GRK2 deletion significantly ameliorates myocardial ␤AR number, signaling, and
function, which probably underlies, in turn, the improvement
in cardiac function.
Cardiac Remodeling and Functional Biomarkers at 4 Weeks
Post-MI—To further analyze morphological and molecular
aspects of adverse cardiac remodeling, we also assessed mRNA
expression levels of specific genes known to play important
roles in HF pathogenesis. The heart weight-to-body weight
ratio was significantly increased in control WT mice at 4 weeks
post-MI compared with the sham groups consistent with a HF
phenotype, while cardiac mass was significantly decreased in
PNMT-driven GRK2 KO mice 4 weeks after MI (Table 2). For
molecular LV remodeling and hypertrophy status characterization, we measured the mRNA levels of collagen 1, atrial natriVOLUME 285 • NUMBER 21 • MAY 21, 2010
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uretic factor, and transforming growth factor-␤1 in the LV of all
groups via reverse transcription-PCR. Consistent with the
echocardiographic data presented above (Fig. 5), collagen 1,
atrial natriuretic factor, and transforming growth factor-␤1
mRNA levels were markedly increased in control WT hearts at

4 weeks post-MI, as expected, and levels of these detrimental
cardiac markers were significantly reduced in PNMT-driven
GRK2 KO hearts over the same post-MI time period (Fig. 8,
A–C). These results demonstrate that the reduction of cardiac
sympathetic activation by the adrenal-specific GRK2 deletion
results in significant attenuation of post-MI HF-related remodeling. Finally, mRNA levels of brain natriuretic peptide (BNP), a
fetal gene marker of cardiac hypertrophy, HF, and volume overload, were measured. Levels of BNP were again markedly elevated in control WT hearts at 4 weeks post-MI as expected,
whereas KO hearts showed significantly lowered BNP expression (Fig. 8D). This favorable change in BNP levels is entirely
consistent with the echocardiographic and hemodynamic analysis results presented above (Fig. 5 and Table 2). Of note, the
adrenal hypertrophy present in WT mice after MI, as expected
(17), appears significantly attenuated in PNMT-driven GRK2
KO mice at 4 weeks post-MI, as well (Table 2).

DISCUSSION

FIGURE 6. Infarct size in PNMT-driven GRK2 KO (KO) and WT mice at 24 h
post-MI. Sham hearts are also shown as negative controls. A, representative
triphenyltetrazolium chloride-stained cardiac cross-sections. B, average LV
infarct size (n ⫽ 5 for each group). No significant difference between the MI
groups was observed (p ⫽ 0.05).

In previous studies, we documented a crucial role for adrenal
GRK2 in regulation of cardiac sympathetic stimulation, both
under normal conditions and in the context of chronic HF (17,
24; reviewed in Ref. 11). In the present study, we sought to
investigate whether suppression of adrenal GRK2 before the
onset of HF can confer any benefit in progressing post-MI HF
by reducing cardiac sympathetic burden. To this end, we developed a new transgenic mouse model having the GRK2 gene
specifically deleted in the chromaffin cells of the adrenal
medulla (PNMT-driven GRK2 KO), by utilizing the well established Cre/loxP technology (19), and we induced chronic HF by
surgical MI in these mice. Our findings show that adrenal-restricted GRK2 deletion indeed leads to a significant reduction
of circulating CAs in vivo in post-MI HF, thus proving the con-

TABLE 2
Cardiac functional parameters in sham and post-MI WT and PNMT-driven GRK2 KO mice
Echocardiographic and hemodynamic analysis data from 3-month-old sham-operated (Sham) or post-MI WT and PNMT-driven GRK2 KO mice on day 28 post-MI.
Analysis of variance with the Bonferroni test was performed among all groups. Data are presented as mean ⫾ S.E. ⫹dP/dtmax, maximal first derivative of LV pressure rise;
⫺dP/dtmin, minimal first derivative of LV pressure fall; HR, heart rate; LVESP, LV end systolic pressure; LVEDP, LV end diastolic pressure; LVIDd, LV inner diameter during
diastole; LVIDs, LV inner diameter during systole; FS, fractional shortening; EF, ejection fraction; PWTd, posterior wall thickness in diastole; HW/BW, heart weight-tobody weight ratio; AW/BW, adrenal weight-to-body weight ratio; and LV, left ventricular.
Sham/WT

Sham/KO

2.34 ⫾ 0.08
3.88 ⫾ 0.15
38.52 ⫾ 0.14
69.6 ⫾ 1.97
0.95 ⫾ 0.05

2.32 ⫾ 0.11
3.96 ⫾ 0.08
39.25 ⫾ 2.39
70.12 ⫾ 3.02
1.00 ⫾ 0.02

4.39 ⫾ 0.12a
4.99 ⫾ 0.12a
13.77 ⫾ 1.13a
30.90 ⫾ 1.65a
1.28 ⫾ 0.01a

Basal hemodynamic measurements
468.2 ⫾ 2.9
HR (min⫺1)
5,430 ⫾ 29
⫹dP/dtmax (mmHg/s)
⫺5,159 ⫾ 206
⫺dP/dtmin (mmHg/s)
LVESP (mmHg)
98.4 ⫾ 1.1
LVEDP (mmHg)
3.8 ⫾ 0.4

477.6 ⫾ 11.5
5,432 ⫾ 49
⫺5,041 ⫾ 101
98.8 ⫾ 1.86
4.0 ⫾ 0.4

457.6 ⫾ 12.5
4,552 ⫾ 63a
⫺4,379 ⫾ 104a
83.43 ⫾ 4.4a
11.2 ⫾ 0.8a

456.3 ⫾ 8.7
4,448 ⫾ 75a
⫺4,298 ⫾ 57a
86.14 ⫾ 1.8a
10.7 ⫾ 1.4a

Hemodynamic measurements after maximal isoproterenol (333 ng/kg BW)
576 ⫾ 17.2
581 ⫾ 7.2
HR (min⫺1)
9,717 ⫾ 740
10,451 ⫾ 230
⫹dP/dtmax (mmHg/s)
⫺8,456 ⫾ 438
⫺8,380 ⫾ 255
⫺dP/dtmin (mmHg/s)
LVESP (mmHg)
101 ⫾ 2.3
101 ⫾ 1.8
LVEDP (mmHg)
4.8 ⫾ 1.4
4.6 ⫾ 0.6

578 ⫾ 13.3
6,689 ⫾ 328a
⫺6,557 ⫾ 392a
86 ⫾ 3.1a
12.4 ⫾ 0.9a

582 ⫾ 7.1
8,273 ⫾ 489a,b
⫺6,647 ⫾ 318a
89 ⫾ 3.4a
12.25 ⫾ 0.5a

9.8 ⫾ 0.32a
0.38 ⫾ 0.06a

8.2 ⫾ 0.09a,b
0.19 ⫾ 0.03a,b

LVIDs (mm)
LVIDd (mm)
FS (%)
EF (%)
PWTd (mm)

Phenotypic data
HW/BW (mg/g)
AW/BW (mg/g)

5.03 ⫾ 0.18
0.09 ⫾ 0.01

5.06 ⫾ 0.13
0.06 ⫾ 0.01c

Post-MI/WT

Post-MI/KO
3.31 ⫾ 0.21a,b
4.69 ⫾ 0.06a,b
20.11 ⫾ 0.35a,b
41.17 ⫾ 0.97a,b
1.11 ⫾ 0.04a,b

p ⬍ 0.05 versus the sham line.
p ⬍ 0.05 versus post-MI/WT.
c
p ⬍ 0.05 versus Sham/WT, n ⫽ 10 mice/group for echo, HW/BW, and AW/BW measurements, n ⫽ 7 mice/group for hemodynamic measurements.

a
b
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FIGURE 7. A, ␤AR density in cardiac plasma membranes of sham-operated (sham) or of 4-week post-MI HF (MI) PNMT-driven GRK2 KO (KO) and control WT mice.
*, p ⬍ 0.01, versus either Sham (**, p ⬍ 0.05 versus MI WT, n ⫽ 6 hearts/group). B, steady-state total cAMP levels in cardiac homogenates purified from hearts of
these mice (*, p ⬍ 0.05 versus all other groups, n ⫽ 6 hearts/group). C, representative Western blots in total cardiac protein extracts from these mice for cardiac
GRK2 protein levels. Blots for the housekeeping protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH), as loading control, are also shown. D, densitometric quantitation of the blots done in C, using GAPDH levels as normalization control (*, p ⬍ 0.05, versus respective Sham, n ⫽ 6 hearts/group).

cept of the transgenic animal approach employed, and, importantly, this resultant reduction of both circulating CAs (NE and
Epi) appears indeed to impede the deterioration of cardiac
function and ␤AR signaling, which are hallmarks of the
post-MI chronic HF progression.
Previously, GRK2 was found, by tightly regulating the activity
and function of the sympatho-inhibitory ␣2ARs of the adrenal
gland and of the central SNS, to be a key regulator of the CA
levels present at the heart at any given time and, hence, of the
levels of cardiac catecholaminergic stimulation, which is an
important factor affecting morbidity and mortality in HF (6, 9).
Moreover, we have shown that adrenal GRK2 inhibition via
adenoviral-mediated in vivo gene therapy acutely decreases circulating CAs and improves cardiac inotropic reserve and function in rats with already established HF (10 weeks post-MI)
(17). With the data from the current study, it is now even clearer
that lowered GRK2 expression and activity in the adrenal gland
can have a significant beneficial impact on the injured heart by
imparting a sympatholytic effect on CA secretion from the
adrenal medulla.
Importantly, the PNMT-driven GRK2 KO mice appear viable and normal and present no gross phenotypic abnormalities.
Interestingly, with regard to their adrenal phenotype, they
appear to have significantly reduced CA biosynthetic activity,
as reflected by the down-regulation of TH present in their adrenals. In addition, the size of their adrenals is reduced compared
with WT animals at 2 months of age (Table 1), and, intriguingly,
they also display significantly attenuated adrenal hypertrophy
at 4 weeks post-MI (Table 2). Thus, adrenal GRK2 seems to be
an important trophic factor for the adrenal gland in health, but
also a major driving force behind adrenal hypertrophy and
hyperfunctioning in HF. These findings are also consistent with
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the up-regulation of adrenal TH and the enhanced adrenal
hypertrophy observed in HF rats, where adrenal GRK2 is also
up-regulated, and also with the reduction of adrenal TH levels
of HF rats observed when adrenal GRK2 is inhibited in vivo (17).
In addition, GRK2 emerges as a critical regulator of adrenal CA
biosynthetic function in general, with its activity driving the
organ toward increased production of CAs. The mechanisms
for this are not clear at the moment. It could very well be an
indirect mechanism, i.e. increased GRK2 leads to enhanced CA
secretion, which in turn forces the adrenal medulla to produce
more CAs to meet the growing demand, but GRK2 might also
be more directly involved in adrenal CA biosynthesis, e.g. via
regulation of specific biosynthetic enzymes. In any case, the
mechanisms of this relationship of GRK2 with CA biosynthetic
function in the adrenal gland will be of great interest to study
and will be the focus of future studies.
Perhaps the most important finding of the present study is
that adrenal-targeted GRK2 deletion caused a substantial
reduction in circulating CAs post-MI, although it did not affect
CA levels in normal, sham-operated mice. This finding confirms that the genetic perturbations employed to create this
PNMT-driven GRK2 KO line did not have any nonspecific,
non-adrenal GRK2-related effects on circulating CAs. More
importantly, it also strongly suggests that adrenal GRK2 is
absolutely crucial for the elevation of CA levels in post-MI HF,
and thus, inhibition/suppression of adrenal GRK2 activity early
on after the occurrence of an MI can have a powerful sympatholytic effect, which is very beneficial in the post-MI HF setting (9, 25).
Admittedly, the reduction in circulating CAs conferred by
adrenal-specific GRK2 deletion in the present study appears
relatively small, perhaps smaller than might have been exVOLUME 285 • NUMBER 21 • MAY 21, 2010
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FIGURE 8. Heart mRNA levels of collagen I (A), atrial natriuretic factor (B), transforming growth factor ␤1 (C), and brain natriuretic peptide (D) in all
experimental groups at 4 weeks post-MI. All values were standardized to amplified 28 S rRNA. Data are presented as mean ⫾ S.E. and plotted as fold of sham
WT values (*, p ⬍ 0.05, versus MI WT, n ⫽ 6 hearts/group).

pected, bringing circulating CA levels nowhere near the normal
(sham) values. However, this can be explained by the fact that,
in the PNMT-driven GRK2 KO model described here, GRK2 is
deleted only in Epi-producing cells and tissues, not in every
sympathetic tissue in the body (20). Therefore, sympathetic
neurons can still produce and release NE normally. On the
other hand, NE can still normally stimulate ␤ARs present in
central (or other) adrenergic/sympathetic neurons, which facilitate NE and/or Epi release (26); thus, even Epi might not be
substantially reduced by the GRK2 deletion in adrenal chromaffin cells. Therefore, when all these parameters are taken
into account, the unchanged (with respect to wild type) CA
levels in normal (sham) PNMT-driven GRK2 KO mice and the
relatively small CA level reductions in these mice observed
post-MI are not all that surprising. Nevertheless, even slight
reductions in the catecholaminergic burden of the failing
heart can have profound beneficial effects on cardiac function and overall clinical status of the HF patient (27). In fact,
excessive plasma CA reduction has been postulated to actually be deleterious rather than beneficial in HF patients (27,
MAY 21, 2010 • VOLUME 285 • NUMBER 21

28). Thus, it is absolutely plausible that the reductions in
circulating CAs we observed in the PNMT-driven GRK2 KO
mice can significantly impact cardiac function and ␤AR signaling post-MI in a beneficial manner.
The final interesting finding of the present study is the
observed down-regulation of GRK2 in the failing hearts of
PNMT-driven GRK2 KO mice. Because myocardial GRK2 critically regulates cardiac ␤AR signaling and function and hence
cardiac performance and its up-regulation post-MI is a major
contributor to the functional worsening of the failing heart (3, 4,
5, 23), this finding is reflective of the improved cardiac ␤AR
signaling and function induced by CA reduction in the HF
PNMT-driven GRK2 KO mice. However, it additionally suggests a close dynamic regulation of myocardial GRK2 activity by
the levels of cardiac catecholaminergic activation (23, 29),
which in turn are tightly regulated by GRK2 activity in the adrenal glands and in the central SNS (11, 17). Thus, the findings of
the present study reinforce the notion that GRK2 is a key molecule in fine-tuning cardiac function, both basally and after
sympathetic stimulation, and in particular in circumstances
JOURNAL OF BIOLOGICAL CHEMISTRY
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where this function is severely compromised, such as in the
chronic HF setting (11).
Overall, the present study reports that adrenal-targeted
GRK2 gene deletion helps halt progression of cardiac contractile dysfunction and adverse remodeling and restores the abnormalities of cardiac ␤AR signaling in post-MI chronic HF by
significantly reducing circulating catecholamine levels after
cardiac injury, which are extremely toxic for the failing heart (6,
25). Of note, the beneficial effects of adrenal-specific GRK2
deletion also include down-regulation of cardiac GRK2, an
important indicator of cardiac dysfunction in HF, and are evident even without a dramatic reduction in CA levels, which
could be detrimental for cardiac hemodynamic support of the
circulation and incompatible with life (27, 28). Thus, reduction
of sympathetic activity/outflow via adrenal GRK2 inhibition as
early as possible in the course of post-MI HF progression
emerges as an attractive therapeutic strategy in the management of LV dysfunction.
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